Home Infusion Therapy MarketSize, Share & Industry Analysis, 2026-2034By Therapy TypeBy ProductBy Service TypeBy Route of AdministrationBy IndicationBy Provider TypeBy Patient Age GroupBy Payer TypeBy Care SettingBy Duration of Therapy
Full title & scope — all 10 axes with their segments
Home Infusion Therapy Market Size, Share & Industry Analysis, By Therapy Type (Anti-Infective Therapy, Parenteral Nutrition, Enteral Nutrition, Immunoglobulin Therapy, Chemotherapy, Pain Management, Hydration Therapy, Inotropic and Cardiac Therapy, Specialty Biologics and Rare Disease Therapies), By Product (Infusion Pumps, IV Sets and Administration Sets, IV Catheters and Access Devices, IV Bags and Containers, Needleless Connectors and Accessories), By Service Type (Pharmacy Compounding and Dispensing, Skilled Nursing and Clinical Services, Equipment Rental and Supply, Patient Training and Care Coordination, Remote Patient Monitoring and Telepharmacy), By Route of Administration (Intravenous, Subcutaneous, Enteral, Epidural and Intrathecal, Intramuscular), By Indication (Infectious Diseases, Cancer, Primary and Secondary Immunodeficiency, Gastrointestinal Disorders and Short Bowel Syndrome, Neurological and Autoimmune Disorders, Hemophilia and Bleeding Disorders, Cardiovascular Disorders, Diabetes, Chronic Pain), By Provider Type (Independent Home Infusion Pharmacies, Hospital-Based Infusion Providers, Payer-Owned Infusion Providers, Specialty Pharmacy-Affiliated Providers, Home Health Agency-Based Providers), By Patient Age Group (Pediatric, Adult, Geriatric), By Payer Type (Medicare, Medicaid and Government Programs, Commercial Insurance, Out-of-Pocket and Self-Pay), By Care Setting (Patient Home, Ambulatory Infusion Suites, Assisted Living Facilities, Skilled Nursing Facilities), By Duration of Therapy (Short-Term (Acute) Therapy, Long-Term (Chronic) Therapy, Intermittent and Episodic Therapy), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.
- 01By Therapy TypeAnti-Infective Therapy · Parenteral Nutrition · Enteral Nutrition
- 02By ProductInfusion Pumps · IV Sets and Administration Sets · IV Catheters and Access Devices
- 03By Service TypePharmacy Compounding and Dispensing · Skilled Nursing and Clinical Services · Equipment Rental and Supply
- 04By Route of AdministrationIntravenous · Subcutaneous · Enteral
- 05By IndicationInfectious Diseases · Cancer · Primary and Secondary Immunodeficiency
- 06By Provider TypeIndependent Home Infusion Pharmacies · Hospital-Based Infusion Providers · Payer-Owned Infusion Providers
- 07By Patient Age GroupPediatric · Adult · Geriatric
- 08By Payer TypeMedicare · Medicaid and Government Programs · Commercial Insurance
- 09By Care SettingPatient Home · Ambulatory Infusion Suites · Assisted Living Facilities
- 10By Duration of TherapyShort-Term · Long-Term · Intermittent and Episodic Therapy
- 11By Region
Market Analysis & Outlook
Home infusion therapy is the delivery of intravenous, subcutaneous, enteral and other infused drugs and nutrition to patients in their own home or other non-hospital settings. It includes the pharmacy compounding, nursing visits, pumps and supplies that make this care possible, and it covers anti-infective, nutrition, immunoglobulin, chemotherapy, pain and specialty biologic therapies. Buyers are insurers and government programmes, health systems that refer patients out of hospital, and patients who pay directly.
USD 41.5 billion of revenue was recorded in the global home infusion therapy market in 2025. By 2034 the figure reaches USD 82.96 billion, a compound annual growth rate of 8% through the forecast period, along a series that runs USD 28.9 billion in 2020, USD 39 billion in 2024, USD 44.82 billion in 2026 and USD 60.98 billion in 2030.
The therapy type mix shifts over the period. Anti-Infective Therapy is the largest line in 2025 at USD 11.2 billion, a 26.99% share, moving to USD 20.16 billion and 24.3% by 2034. Specialty Biologics and Rare Disease Therapies grows fastest at 12.75%, taking its share from 12% to 17.85%, while Hydration Therapy grows slowest at 5.44%. The lines gaining share are Immunoglobulin Therapy and Specialty Biologics and Rare Disease Therapies. Anti-Infective Therapy, Parenteral Nutrition, Enteral Nutrition, Chemotherapy, Pain Management, Hydration Therapy and Inotropic and Cardiac Therapy lose share without losing revenue.
By product, Infusion Pumps accounts for 30% of 2025 revenue at USD 12.45 billion, reaching USD 27.38 billion and 33% by 2034. Needleless Connectors and Accessories grows faster at 9.16% against 9.15%, moving from 10% of revenue to 11.01% by 2034. This axis divides the same revenue as the therapy type split instead of adding to it, so the two are read together and never summed.
The 2025 total is arrived at by triangulating published aggregates against category proxies, not by an independent count. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, nine therapy type lines and ten segmentation axes across a fifteen-year window.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global home infusion therapy market moves from USD 28.9 billion in 2020 to USD 41.5 billion in 2025 and USD 82.96 billion by 2034, the forecast period compounding at 8% a year.
- The largest line by therapy type is Anti-Infective Therapy, worth USD 11.2 billion and 26.99% of revenue in 2025, rising to USD 20.16 billion and 24.3% by 2034.
- At 12.75%, Specialty Biologics and Rare Disease Therapies grows faster than any other therapy type line, moving from USD 4.98 billion and 12% of revenue in 2025 to USD 14.81 billion and 17.85% in 2034.
- Scenario range for 2034 runs from USD 74 billion in the bear case to USD 91.92 billion in the bull case, against a base-case USD 82.96 billion, the spread a plan built on this forecast has to absorb.
- 94.1% of North America's base-year revenue comes from the United States alone: USD 20.3 billion in 2025, rising to USD 36.9 billion by 2034, which is why it is that region's worked example.
- Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.
Market Trends
Revenue Share, By therapy type
Base year 2025Anti-Infective Therapy leads with 27.0% of therapy type segment revenue.
Share of therapy type segment revenue, most recent base year. The 3 smallest segments are grouped as Other.
Read across the forecast period, the global home infusion therapy market shows movement in three places: therapy type composition, regional weight, and the 8% rate applied to the whole.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
The therapy type mix tilts toward Specialty Biologics and Rare Disease Therapies. The widest spread on the therapy type axis is between Specialty Biologics and Rare Disease Therapies at 12.75% and Hydration Therapy at 5.44%. By 2034 the two sit at 17.85% and 5.65% of revenue, against 12% and 6.99% in 2025. Neither contracts: USD 4.98 billion becomes USD 14.81 billion, USD 2.9 billion becomes USD 4.69 billion. What the spread decides is which of them a supplier's revenue is exposed to.
Every region grows, none at another's expense. Nothing in the regional split changes hands over the forecast period, which turns regional strategy into a capacity question, not a competitive one.
Fifteen years without a discontinuity. The market moves through USD 28.9 billion in 2020, USD 39 billion in 2024, USD 41.5 billion in 2025, USD 44.82 billion in 2026, USD 60.98 billion in 2030 and USD 82.96 billion in 2034. Against 7.51% through the historical period, the 8% forecast rate is a continuation; no year in the series interrupts it. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the therapy type and regional axes, not by the headline rate.
Market Growth Factors
Specialty Biologics and Rare Disease Therapies carries the market's growth rate
Market Drivers
3- 01Specialty Biologics and Rare Disease Therapies carries the market's growth rate
The fastest line on the therapy type axis is Specialty Biologics and Rare Disease Therapies, at 12.75% against the market's 8%, taking USD 4.98 billion to USD 14.81 billion and 12% of revenue to 17.85%. Nothing else on the axis grows as fast (Hydration Therapy manages 5.44%) so the blended 8% is carried by this one line instead of shared across them. A portfolio weighted away from it tracks below the market even in a market growing everywhere.
- 02Growth lands where the revenue already is
Between them they hold most of the base and most of the revenue added over the period, so equal-weighting the regions in a plan misstates where the growth is.
- 03Fifteen years of unbroken growth underpin the forecast
Revenue rose through USD 28.9 billion in 2020, USD 39 billion in 2024 and USD 41.5 billion in 2025, a compound 7.51% across the historical period. From there the forecast carries 8% through to USD 82.96 billion in 2034. Fifteen years of unbroken growth in the series means the forecast rests on a demonstrated trajectory, not a projected turnaround, and it is why the 8% rate is applied flat across the whole period instead of ramped through it.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Shift of infusion care from hospitals to the home | High | +15 | High | High | Medium |
| 2 | Growth of specialty biologics and rare disease therapies | High | +11 | Medium | High | High |
| 3 | Ageing population and chronic disease prevalence | Medium-High | +8 | Medium | Medium | High |
| 4 | Payer pressure toward lower cost care settings | Medium | +6 | High | Medium | Medium |
| 5 | Others | Low | +3.5 | Low | Low | Low |
| Total | +43.5 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Reimbursement gaps and prior authorization friction | Medium | −1.2 | Medium | Medium | Low |
| 2 | Nursing and pharmacy workforce shortages | Medium | −0.84 | High | Medium | Medium |
| Total | −2.04 | |||||
Drivers contribute 43.5 USD Billion and restraints remove 2.04 USD Billion, a net 41.46 USD Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 8% into its parts and three show up: an already-large base compounding, the therapy type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
A bear case of USD 74 billion in 2034, against USD 82.96 billion in the base case, rests on one stated assumption: slower coverage expansion, nursing shortages and tighter payer controls on infusion drugs hold growth below the base path. Neither case changes the USD 41.5 billion 2025 base.
- 02Anti-Infective Therapy holds the blended rate down
Anti-Infective Therapy carries 26.99% of 2025 revenue at USD 11.2 billion but compounds at 6.73% against 8% for the market, taking its share to 24.3% by 2034 even as revenue rises to USD 20.16 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Upside case: USD 91.92 billion by 2034
Market Opportunities
2- 01Upside case: USD 91.92 billion by 2034
Faster site-of-care transfer, wider payer coverage for home infusion drugs and quicker uptake of subcutaneous biologics lift growth above the base path. On that assumption the market reaches USD 91.92 billion by 2034 against USD 82.96 billion in the base case, from the same USD 41.5 billion in 2025.
- 02The opening is on the therapy type axis, not the regional one
Specialty Biologics and Rare Disease Therapies grows at 12.75% against 8% for the market, adding revenue from USD 4.98 billion in 2025 to USD 14.81 billion in 2034 and taking its share from 12% to 17.85%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Anti-Infective Therapy.
Market Challenges
Concentration on the therapy type axis
Market Challenges
2- 01Concentration on the therapy type axis
USD 11.2 billion of 2025 revenue sits in Anti-Infective Therapy, 26.99% of the total, and it is still 24.3% at USD 20.16 billion nine years later. That concentration means the market's own forecast is, to a large extent, a forecast for one therapy type line.
- 02Single-country exposure in North America
The United States generates USD 20.3 billion of North America's USD 21.58 billion in 2025, 94.1% of the region, reaching USD 36.9 billion by 2034. A regional number that depends this heavily on one country carries that country's specific conditions inside it, which a reader treating the region as diversified would miss.
Segmentation Analysis
10 axesThe global home infusion therapy market is cut ten ways: by therapy type, product, service type, route of administration, indication, provider type, patient age group, payer type, care setting and duration of therapy. Revenue does not add across them: each is a different cut of the same total.
All nine therapy type lines expand in revenue terms over the forecast period. Share is the dividing line; two take it, the others cede it.
By Therapy Type · 9 segments
By Therapy Type
- Largest Anti-Infective Therapy · 27%
- Fastest Specialty Biologics and Rare Disease Therapies · 12.8%
- Moves most Specialty Biologics and Rare Disease Therapies · +5.9 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Anti-Infective Therapy | $11.20B | 27% | $20.16B | 24.3%-2.7 | 6.7% |
| Parenteral Nutrition | $5.81B | 14% | $10.87B | 13.1%-0.9 | 7.2% |
| Enteral Nutrition | $2.49B | 6% | $4.60B | 5.5%-0.5 | 7% |
| Immunoglobulin Therapy | $4.98B | 12% | $10.70B | 12.9%+0.9 | 8.9% |
| Chemotherapy | $4.15B | 10% | $8.30B | 10% | 8% |
| Pain Management | $2.91B | 7% | $5.06B | 6.1%-0.9 | 6.4% |
| Hydration Therapy | $2.90B | 7% | $4.69B | 5.7%-1.3 | 5.4% |
| Inotropic and Cardiac Therapy | $2.08B | 5% | $3.77B | 4.5%-0.5 | 6.8% |
| Specialty Biologics and Rare Disease Therapies | $4.98B | 12% | $14.81B | 17.9%+5.9 | 12.8% |
2025 to 2034 revenue and share by line: Anti-Infective Therapy USD 11.2 billion to USD 20.16 billion (26.99% in 2025), Parenteral Nutrition USD 5.81 billion to USD 10.87 billion (14% in 2025), Immunoglobulin Therapy USD 4.98 billion to USD 10.7 billion (12% in 2025), Specialty Biologics and Rare Disease Therapies USD 4.98 billion to USD 14.81 billion (12% in 2025), Chemotherapy USD 4.15 billion to USD 8.3 billion (10% in 2025), Pain Management USD 2.91 billion to USD 5.06 billion (7.01% in 2025), Hydration Therapy USD 2.9 billion to USD 4.69 billion (6.99% in 2025), Enteral Nutrition USD 2.49 billion to USD 4.6 billion (6% in 2025), Inotropic and Cardiac Therapy USD 2.08 billion to USD 3.77 billion (5.01% in 2025). Anti-Infective Therapy Held the Dominant Share of the Therapy type Segment in 2025 Anti-infective therapy leads because long antibiotic courses for bone, skin and bloodstream infections moved home early and the patient pool is large and steady. Specialty biologics and rare disease therapies grow fastest as new biologic and enzyme treatments are approved, many of them given by infusion, and as payers prefer the home to hospital outpatient settings for these costly drugs. By 2034 Anti-Infective Therapy is still ahead, making this a shift in weight, not a change of leader. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.
By Product · 5 segments
Needleless Connectors and Accessories Outpaces the Axis While Infusion Pumps Holds the Largest Share
- Largest Infusion Pumps · 30%
- Fastest Needleless Connectors and Accessories · 9.2%
- Moves most Infusion Pumps · +3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Infusion Pumps | $12.45B | 30% | $27.38B | 33%+3 | 9.2% |
| IV Sets and Administration Sets | $9.96B | 24% | $18.25B | 22%-2 | 7% |
| IV Catheters and Access Devices | $9.13B | 22% | $18.25B | 22% | 8% |
| IV Bags and Containers | $5.81B | 14% | $9.95B | 12%-2 | 6.2% |
| Needleless Connectors and Accessories | $4.15B | 10% | $9.13B | 11%+1 | 9.2% |
Infusion pumps hold the largest line because every home programme needs programmable delivery, and pumps carry the highest unit price and a long replacement cycle. Needleless connectors and accessories grow fastest as infection control rules spread and as more patients keep central lines in place at home, which raises demand for these single use components. The order does not change: Infusion Pumps is still largest in 2034, and what moves is how much it holds.
By Service Type · 5 segments
Pharmacy Compounding and Dispensing Led by Service type in 2025, with Remote Patient Monitoring and Telepharmacy Growing Fastest
- Largest Pharmacy Compounding and Dispensing · 38%
- Fastest Remote Patient Monitoring and Telepharmacy · 14.7%
- Moves most Remote Patient Monitoring and Telepharmacy · +5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pharmacy Compounding and Dispensing | $15.77B | 38% | $28.21B | 34%-4 | 6.7% |
| Skilled Nursing and Clinical Services | $10.79B | 26% | $20.74B | 25%-1 | 7.5% |
| Equipment Rental and Supply | $7.47B | 18% | $14.10B | 17%-1 | 7.3% |
| Patient Training and Care Coordination | $4.57B | 11% | $9.96B | 12%+1 | 9% |
| Remote Patient Monitoring and Telepharmacy | $2.90B | 7% | $9.95B | 12%+5 | 14.7% |
Pharmacy compounding and dispensing leads because sterile preparation of each patient's drug is the core paid service and carries the drug margin. Remote monitoring and telepharmacy grow fastest as providers try to cover more patients with limited nursing staff and as payers reward early detection of complications, which reduces avoidable readmissions. The order does not change: Pharmacy Compounding and Dispensing is still largest in 2034, and what moves is how much it holds.
By Route of Administration · 5 segments
Scale in Intravenous and Growth in Subcutaneous Define the Route of administration Axis
- Largest Intravenous · 72%
- Fastest Subcutaneous · 12.4%
- Moves most Intravenous · -6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Intravenous | $29.88B | 72% | $54.75B | 66%-6 | 7% |
| Subcutaneous | $5.81B | 14% | $16.59B | 20%+6 | 12.4% |
| Enteral | $3.32B | 8% | $6.64B | 8% | 8% |
| Epidural and Intrathecal | $1.25B | 3% | $2.49B | 3% | 8% |
| Intramuscular | $1.24B | 3% | $2.49B | 3% | 8.1% |
The intravenous route leads because most infused antibiotics, nutrition, chemotherapy and immunoglobulin products still need a vein. Subcutaneous administration grows fastest as drugmakers reformulate products for under the skin delivery, using enzyme assisted dosing and pump driven infusion, which shortens visits and lets patients treat themselves with less nursing input. The order does not change: Intravenous is still largest in 2034, and what moves is how much it holds.
By Indication · 9 segments
By Indication
- Largest Infectious Diseases · 24%
- Fastest Neurological and Autoimmune Disorders · 13.4%
- Moves most Neurological and Autoimmune Disorders · +5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Infectious Diseases | $9.96B | 24% | $16.59B | 20%-4 | 5.8% |
| Cancer | $8.30B | 20% | $15.76B | 19%-1 | 7.4% |
| Primary and Secondary Immunodeficiency | $4.98B | 12% | $9.96B | 12% | 8% |
| Gastrointestinal Disorders and Short Bowel Syndrome | $4.98B | 12% | $9.12B | 11%-1 | 7% |
| Neurological and Autoimmune Disorders | $3.74B | 9% | $11.61B | 14%+5 | 13.4% |
| Hemophilia and Bleeding Disorders | $2.49B | 6% | $4.98B | 6% | 8% |
| Cardiovascular Disorders | $2.49B | 6% | $4.15B | 5%-1 | 5.8% |
| Diabetes | $2.07B | 5% | $4.98B | 6%+1 | 10.3% |
| Chronic Pain | $2.49B | 6% | $5.81B | 7%+1 | 9.9% |
2025 to 2034 revenue and share by line: Infectious Diseases USD 9.96 billion to USD 16.59 billion (24% in 2025), Cancer USD 8.3 billion to USD 15.76 billion (20% in 2025), Primary and Secondary Immunodeficiency USD 4.98 billion to USD 9.96 billion (12% in 2025), Gastrointestinal Disorders and Short Bowel Syndrome USD 4.98 billion to USD 9.12 billion (12% in 2025), Neurological and Autoimmune Disorders USD 3.74 billion to USD 11.61 billion (9.01% in 2025), Hemophilia and Bleeding Disorders USD 2.49 billion to USD 4.98 billion (6% in 2025), Cardiovascular Disorders USD 2.49 billion to USD 4.15 billion (6% in 2025), Chronic Pain USD 2.49 billion to USD 5.81 billion (6% in 2025), Diabetes USD 2.07 billion to USD 4.98 billion (4.99% in 2025). Scale in Infectious Diseases and Growth in Neurological and Autoimmune Disorders Define the Indication Axis Infectious diseases lead because long courses of intravenous antibiotics for bone, joint and deep tissue infections are the longest established home infusion use. Neurological and autoimmune disorders grow fastest as immunoglobulin and monoclonal antibody infusions are used for more conditions and as patients and payers favour home delivery over repeated hospital visits. Infectious Diseases remains the largest line through 2034, so the axis changes in proportion, not in order.
By Provider Type · 5 segments
Independent Home Infusion Pharmacies Led by Provider type in 2025, with Payer-Owned Infusion Providers Growing Fastest
- Largest Independent Home Infusion Pharmacies · 34%
- Fastest Payer-Owned Infusion Providers · 10.2%
- Moves most Independent Home Infusion Pharmacies · -4 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Independent Home Infusion Pharmacies | $14.11B | 34% | $24.89B | 30%-4 | 6.5% |
| Hospital-Based Infusion Providers | $7.47B | 18% | $14.10B | 17%-1 | 7.3% |
| Payer-Owned Infusion Providers | $8.30B | 20% | $19.91B | 24%+4 | 10.2% |
| Specialty Pharmacy-Affiliated Providers | $6.64B | 16% | $14.93B | 18%+2 | 9.4% |
| Home Health Agency-Based Providers | $4.98B | 12% | $9.13B | 11%-1 | 7% |
Independent home infusion pharmacies lead because they developed the clinical model and hold broad payer contracts and local referral ties. Payer-owned providers grow fastest as insurers steer members toward their own pharmacies to control spend and keep care coordinated, using claims data and a stronger bargaining position with drug suppliers. By 2034 Independent Home Infusion Pharmacies is still ahead, making this a shift in weight, not a change of leader.
By Patient Age Group · 3 segments
Adult Held the Dominant Share of the Patient age group Segment in 2025
- Largest Adult · 56%
- Fastest Geriatric · 9.8%
- Moves most Geriatric · +5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pediatric | $4.98B | 12% | $9.13B | 11%-1 | 7% |
| Adult | $23.24B | 56% | $43.14B | 52%-4 | 7.1% |
| Geriatric | $13.28B | 32% | $30.69B | 37%+5 | 9.8% |
Adults lead because most chronic and acute conditions treated by infusion occur in working age and middle aged populations, and adults have the widest access to coverage. Geriatric patients grow fastest as the elderly population expands, multiple chronic conditions become more common and families and payers prefer treatment at home to hospital or facility stays. By 2034 Adult is still ahead, making this a shift in weight, not a change of leader.
By Payer Type · 4 segments
Commercial Insurance Led by Payer type in 2025, with Out-of-Pocket and Self-Pay Growing Fastest
- Largest Commercial Insurance · 40%
- Fastest Out-of-Pocket and Self-Pay · 9.2%
- Moves most Medicare · -1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Medicare | $14.94B | 36% | $29.04B | 35%-1 | 7.7% |
| Medicaid and Government Programs | $5.81B | 14% | $11.61B | 14% | 8% |
| Commercial Insurance | $16.60B | 40% | $33.18B | 40% | 8% |
| Out-of-Pocket and Self-Pay | $4.15B | 10% | $9.13B | 11%+1 | 9.2% |
Commercial insurance leads because private plans cover the broadest range of home infusion drugs and pay full per diem rates for nursing and pharmacy services. Out-of-pocket and self-pay spending grows fastest from a small base as patients pay for convenience, newer therapies outside coverage and services in markets without public home infusion benefits. The order does not change: Commercial Insurance is still largest in 2034, and what moves is how much it holds.
By Care Setting · 4 segments
Scale in Patient Home and Growth in Assisted Living Facilities Define the Care setting Axis
- Largest Patient Home · 78%
- Fastest Assisted Living Facilities · 11.5%
- Moves most Patient Home · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Patient Home | $32.37B | 78% | $61.39B | 74%-4 | 7.4% |
| Ambulatory Infusion Suites | $4.57B | 11% | $10.78B | 13%+2 | 10% |
| Assisted Living Facilities | $2.49B | 6% | $6.64B | 8%+2 | 11.5% |
| Skilled Nursing Facilities | $2.07B | 5% | $4.15B | 5% | 8% |
The patient home leads because it is the lowest cost site, the one payers target and the one most patients prefer for long courses. Assisted living facilities grow fastest as more elderly patients live in these settings and operators build infusion capability to avoid moving residents to hospitals for treatment. Patient Home remains the largest line through 2034, so the axis changes in proportion, not in order.
By Duration of Therapy · 3 segments
Long-Term (Chronic) Therapy Both Leads the Duration of therapy Axis and Grows Fastest on It
- Largest Long-Term (Chronic) Therapy · 55%
- Fastest Long-Term (Chronic) Therapy · 9.1%
- Moves most Long-Term (Chronic) Therapy · +5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Short-Term (Acute) Therapy | $12.45B | 30% | $21.57B | 26%-4 | 6.3% |
| Long-Term (Chronic) Therapy | $22.83B | 55% | $49.78B | 60%+5 | 9.1% |
| Intermittent and Episodic Therapy | $6.22B | 15% | $11.61B | 14%-1 | 7.2% |
Long-term therapy leads and also grows fastest, because parenteral nutrition, immunoglobulin and many biologic regimens continue for months or years and keep generating pharmacy, nursing and supply revenue. Growth comes from more patients starting maintenance biologics at home and from better survival in conditions that require lasting infusion support. The order does not change: Long-Term (Chronic) Therapy is still largest in 2034, and what moves is how much it holds.
Regional Insights
North America Market Analysis
with USD 39.41 billion projected for 2034. Among the five regions it ranks first by revenue in both years.
, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Within the region the therapy type split tracks the global one; 26.99% of 2025 revenue in Anti-Infective Therapy, fastest growth of 12.75% in Specialty Biologics and Rare Disease Therapies. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 94.1% of it, growing 1.8×.
- In region 1 of 2
- Of region 94.1%
- Of global 48.9%
- Revenue $20.30B → $36.90B
The largest single market in North America is the United States, at USD 20.3 billion in 2025 and USD 36.9 billion in 2034. Carrying 94.1% of the region in the base year, it sets North America's direction instead of merely contributing to it. Against regional totals of USD 21.58 billion in 2025 and USD 39.41 billion in 2034, it is the country the full report breaks out in detail.
Composition here matches the global split: the largest line is Anti-Infective Therapy at 26.99% of 2025 revenue, easing to 24.3% by 2034, and the fastest is Specialty Biologics and Rare Disease Therapies at 12.75%, from 12% to 17.85%. Since 94.1% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Revenue by therapy type for the United States is reported separately in the full report.
Home infusion therapy in the United States combines product regulation with service oversight. The Food and Drug Administration regulates infusion pumps, administration sets and catheters as medical devices under its risk-based classification system, with premarket notification or approval depending on the class, and it regulates the infused drugs and compounded preparations through its drug approval and quality provisions. Suppliers must follow quality system and labelling requirements, report adverse events and register their establishments. Pharmacies preparing sterile admixtures also answer to state boards of pharmacy and to the compounding standards published by the United States Pharmacopeia. Medicare supplier standards govern reimbursement eligibility for infusion providers.
Option Care Health, Inc., Optum Infusion Pharmacy (UnitedHealth Group Incorporated), Coram (CVS Health Corporation), BrightSpring Health Services, Inc., Amerita, Inc., KabaFusion, Baxter International Inc., B. Braun Melsungen AG, BD (Becton, Dickinson and Company), ICU Medical, Inc., Fresenius Kabi AG, Soleo Health, Triple Crown Infusion Services, Vivo Infusion, Premier Infusion Care, Wellsky Corporation (CareCentrix), Avant Healthcare Professionals, ARJ Infusion Services, Eversana Life Science Services LLC, Smiths Medical (ICU Medical), Moog Medical Devices Group, Terumo Corporation, Nipro Corporation, Zyno Medical, InfuSystem Holdings, Inc., Sanofi (Home infusion support), Takeda Pharmaceutical Company Limited, CSL Behring (CSL Limited), Fresenius Kabi Home Care, Medline Industries, LP, Apria Healthcare Group, Lincare Holdings Inc., Linde Healthcare Homecare, Vitalaire (Air Liquide Santé) and Orkla Care are the suppliers covered in the United States. Volume sits in Anti-Infective Therapy at 26.99% of 2025 revenue; movement sits in Specialty Biologics and Rare Disease Therapies at 12.75% growth. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.
Canada
2nd-largest in North America, growing 2.0×.
- In region 2 of 2
- Of region 4.9%
- Of global 2.5%
- Revenue $1.05B → $2.10B
Canada is sized at USD 1.05 billion in 2025, rising to USD 2.1 billion by 2034; 2.5% of global revenue and 4.9% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Europe Market Analysis
and reaches USD 16.68 billion by 2034. It is a marginal region on this axis, second by revenue throughout the period.
, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Anti-Infective Therapy is again the largest therapy type line in Europe, as it is everywhere the study reports. The full report breaks Europe out along every axis and by country.
Germany
The largest market in Europe, growing 1.9×.
- In region 1 of 3
- Of region 25.3%
- Of global 5.3%
- Revenue $2.20B → $4.10B
The largest single market in Europe is Germany, at USD 2.2 billion in 2025 and USD 4.1 billion in 2034. 25.3% of the region in the base year makes it the largest market here without making it the region. Set against USD 8.71 billion and USD 16.68 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
The therapy type lines rank in Germany as they do worldwide, with Anti-Infective Therapy the largest line and Specialty Biologics and Rare Disease Therapies gaining share fastest, so its contribution to Europe comes from scale and not from an unusual mix. Since 25.3% of Europe's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Germany carries its own therapy type breakdown in the full report.
In Germany, infusion pumps and related devices used at home fall under the EU Medical Device Regulation, so a supplier needs a risk-based classification, a conformity assessment by a notified body for higher classes, and CE marking before sale. Labelling, unique device identification and post-market surveillance duties apply. The Federal Institute for Drugs and Medical Devices oversees vigilance reporting, while the infused medicines are authorised through the European Medicines Agency or national procedures and manufactured under good manufacturing practice. Pharmacies that prepare individual infusions are supervised by state authorities under the German pharmacy and medicines laws, and statutory health insurers set the terms for reimbursed home care.
Suppliers in Germany are the same companies covered above, Option Care Health, Inc. and Optum Infusion Pharmacy (UnitedHealth Group Incorporated) included; none of them is specific to this market, so position here follows position on the therapy type axis. Two different problems sit on the same axis: holding Anti-Infective Therapy at 26.99% of 2025 revenue, and taking Specialty Biologics and Rare Disease Therapies while it grows at 12.75%. The commercial size of that position is USD 8.71 billion in 2025, moving to USD 16.68 billion by 2034 across the forecast period.
United Kingdom
2nd-largest in Europe, growing 2.0×.
- In region 2 of 3
- Of region 17.8%
- Of global 3.7%
- Revenue $1.55B → $3.05B
The United Kingdom is sized at USD 1.55 billion in 2025, rising to USD 3.05 billion by 2034; 3.7% of global revenue and 17.8% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
France
3rd-largest in Europe, growing 2.0×.
- In region 3 of 3
- Of region 15.5%
- Of global 3.3%
- Revenue $1.35B → $2.65B
France is sized at USD 1.35 billion in 2025, rising to USD 2.65 billion by 2034; 3.3% of global revenue and 15.5% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Asia Pacific Market Analysis
rising to USD 17.46 billion in 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.
, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Nothing in Asia Pacific's therapy type mix departs from the global order, so Anti-Infective Therapy leads here too. The full report breaks Asia Pacific out along every axis and by country.
China
The largest market in Asia Pacific, growing 2.9×.
- In region 1 of 3
- Of region 27.6%
- Of global 4.7%
- Revenue $1.95B → $5.60B
27.6% of Asia Pacific's base-year revenue comes from China; USD 1.95 billion, rising to USD 5.6 billion by 2034. It accounts for 27.6% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 7.06 billion in 2025 and USD 17.46 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Nothing about the therapy type mix sets China apart, with Anti-Infective Therapy the largest line and Specialty Biologics and Rare Disease Therapies gaining share fastest exactly as at global level; the regional effect comes from how much of Asia Pacific it holds. Because the country carries 27.6% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. China carries its own therapy type breakdown in the full report.
In China, the National Medical Products Administration regulates infusion pumps, sets and related devices through a three-tier classification, with registration or filing required according to risk, and imported products must be registered before they can be sold. Domestic manufacturers need a production licence and must follow national device standards and labelling rules, including Chinese-language instructions. Infused drugs are approved by the same agency under the Drug Administration Law and must meet good manufacturing practice. Home-based infusion services are still shaped by health commission rules on medical institutions and nursing practice, so a supplier usually works through licensed hospitals or qualified providers.
China has no supplier set of its own: the companies tracked for the market as a whole, Option Care Health, Inc. and Optum Infusion Pharmacy (UnitedHealth Group Incorporated) among them, compete across its therapy type lines. Two different problems sit on the same axis: holding Anti-Infective Therapy at 26.99% of 2025 revenue, and taking Specialty Biologics and Rare Disease Therapies while it grows at 12.75%. The commercial size of that position is USD 7.06 billion in 2025, moving to USD 17.46 billion by 2034 across the forecast period.
Japan
2nd-largest in Asia Pacific, growing 2.1×.
- In region 2 of 3
- Of region 22.7%
- Of global 3.9%
- Revenue $1.60B → $3.30B
3.9% of global revenue is generated in Japan; USD 1.6 billion in 2025, reaching USD 3.3 billion in 2034, and 22.7% of Asia Pacific.
India
3rd-largest in Asia Pacific, growing 3.5×.
- In region 3 of 3
- Of region 9.2%
- Of global 1.6%
- Revenue $0.65B → $2.30B
India is sized at USD 0.65 billion in 2025, rising to USD 2.3 billion by 2034; 1.6% of global revenue and 9.2% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Latin America Market Analysis
with USD 4.89 billion projected for 2034. It is a marginal region on this axis, fourth by revenue throughout the period.
, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.
Buyers in Latin America take the same therapy type lines in the same order as the market overall, with Anti-Infective Therapy the largest. Latin America is reported axis by axis and country by country in the full study.
Brazil
The largest market in Latin America, growing 2.3×.
- In region 1 of 2
- Of region 50.5%
- Of global 2.5%
- Revenue $1.05B → $2.45B
Brazil is the largest market within Latin America, generating USD 1.05 billion in 2025 and projected to reach USD 2.45 billion by 2034. It accounts for 50.5% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 2.08 billion in 2025 and USD 4.89 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in Brazil follows the same therapy type order as the global market, with Anti-Infective Therapy the largest line and Specialty Biologics and Rare Disease Therapies gaining share fastest, so what changes the picture here is the country's weight in Latin America, not a different mix. With 50.5% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by therapy type for Brazil is reported separately in the full report.
In Brazil, the national health surveillance agency, ANVISA, regulates infusion devices and the medicines delivered through them. Medical devices are classified by risk, and a supplier must obtain registration or notification from ANVISA before marketing, with a Brazilian registration holder required for foreign manufacturers. Products must show conformity with applicable technical standards, carry labelling in Portuguese and meet good manufacturing practice, which ANVISA verifies through inspection. Medicines used in infusion require marketing authorisation from the same agency. Home care services themselves are regulated by ANVISA rules on home care providers, and private health plans are governed by the national supplementary health agency.
Brazil is contested by the same suppliers named for North America, Option Care Health, Inc. and Optum Infusion Pharmacy (UnitedHealth Group Incorporated) among them, selling into the therapy type lines described above, not into a market of its own. Two different problems sit on the same axis: holding Anti-Infective Therapy at 26.99% of 2025 revenue, and taking Specialty Biologics and Rare Disease Therapies while it grows at 12.75%. A supplier weighted toward Latin America is competing over a base of USD 2.08 billion in 2025, reaching USD 4.89 billion by 2034 on the trajectory this study models.
Mexico
2nd-largest in Latin America, growing 2.4×.
- In region 2 of 2
- Of region 26.4%
- Of global 1.3%
- Revenue $0.55B → $1.30B
Mexico is sized at USD 0.55 billion in 2025, rising to USD 1.3 billion by 2034; 1.3% of global revenue and 26.4% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Middle East and Africa Market Analysis
rising to USD 4.52 billion in 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.
, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
The therapy type split here is the one described for North America, led by Anti-Infective Therapy. The full report breaks Middle East and Africa out along every axis and by country.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.4×.
- In region 1 of 3
- Of region 21.7%
- Of global 1.1%
- Revenue $0.45B → $1.10B
The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.45 billion in 2025 and USD 1.1 billion in 2034. It accounts for 21.7% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 2.07 billion in 2025 and USD 4.52 billion in 2034, it is the country the full report breaks out in detail.
Saudi Arabia buys the therapy type lines in the global order, with Anti-Infective Therapy the largest line and Specialty Biologics and Rare Disease Therapies gaining share fastest; the country's size in the region is the figure that matters here. Its 21.7% weight in Middle East and Africa means those movements carry straight into the regional totals. Per-therapy type revenue for Saudi Arabia appears on its own in the full report.
In Saudi Arabia, the Saudi Food and Drug Authority regulates medical devices and medicines used in home infusion. Devices are classified by risk and must be listed through the authority's marketing authorisation process, which requires an authorised representative based in the Kingdom for foreign manufacturers. Suppliers must provide technical documentation, evidence of conformity with recognised international standards, and Arabic and English labelling. Medicines need product registration and compliance with good manufacturing practice. The Ministry of Health licenses healthcare facilities and home healthcare providers, and it sets the practice requirements that infusion services must meet when treating patients outside a hospital.
The supplier field in Saudi Arabia is the one this study tracks globally, led by names such as Option Care Health, Inc. and Optum Infusion Pharmacy (UnitedHealth Group Incorporated), and they compete here on the same therapy type lines. Two different problems sit on the same axis: holding Anti-Infective Therapy at 26.99% of 2025 revenue, and taking Specialty Biologics and Rare Disease Therapies while it grows at 12.75%. The commercial size of that position is USD 2.07 billion in 2025, moving to USD 4.52 billion by 2034 across the forecast period.
South Africa
2nd-largest in Middle East and Africa, growing 2.2×.
- In region 2 of 3
- Of region 14.5%
- Of global 0.7%
- Revenue $0.30B → $0.65B
0.7% of global revenue is generated in South Africa; USD 0.3 billion in 2025, reaching USD 0.65 billion in 2034, and 14.5% of Middle East and Africa.
United Arab Emirates
3rd-largest in Middle East and Africa, growing 2.5×.
- In region 3 of 3
- Of region 13.5%
- Of global 0.7%
- Revenue $0.28B → $0.70B
Within Middle East and Africa, the United Arab Emirates accounts for 13.5% of regional revenue and 0.7% of the global total, worth USD 0.28 billion in 2025 and USD 0.7 billion by 2034.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by therapy type, product, service type, route of administration, indication, provider type, patient age group, payer type, care setting, duration of therapy, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in Anti-Infective Therapy and Growth in Specialty Biologics and Rare Disease Therapies Set the Terms of Competition
Suppliers in scope: Option Care Health, Inc., Optum Infusion Pharmacy (UnitedHealth Group Incorporated), Coram (CVS Health Corporation), BrightSpring Health Services, Inc., Amerita, Inc., KabaFusion, Baxter International Inc., B. Braun Melsungen AG, BD (Becton, Dickinson and Company), ICU Medical, Inc., Fresenius Kabi AG, Soleo Health, Triple Crown Infusion Services, Vivo Infusion, Premier Infusion Care, Wellsky Corporation (CareCentrix), Avant Healthcare Professionals, ARJ Infusion Services, Eversana Life Science Services LLC, Smiths Medical (ICU Medical), Moog Medical Devices Group, Terumo Corporation, Nipro Corporation, Zyno Medical, InfuSystem Holdings, Inc., Sanofi (Home infusion support), Takeda Pharmaceutical Company Limited, CSL Behring (CSL Limited), Fresenius Kabi Home Care, Medline Industries, LP, Apria Healthcare Group, Lincare Holdings Inc., Linde Healthcare Homecare, Vitalaire (Air Liquide Santé) and Orkla Care.
The competitive line that matters is the therapy type one, not the geographic one. Anti-Infective Therapy is 26.99% of 2025 revenue at USD 11.2 billion and still 24.3% in 2034, so it is where the volume sits and where an incumbent's position is hardest to move. Share moves in Specialty Biologics and Rare Disease Therapies, growing 12.75% against 5.44% for Hydration Therapy. The two rarely sit with the same supplier, and that is the reason a USD 41.5 billion market is not already consolidated.
Suppliers separate on sterile compounding capacity and accreditation across many states, and on the ability to deliver drugs and nursing visits within narrow time windows. Payer contracts and in-network status decide referral volume, so scale in negotiating with commercial and government plans favours the largest providers. Device makers compete on pump reliability, software integration and the breadth of administration sets they supply. Smaller and regional providers win on local clinical relationships, faster patient start times and a focus on single therapies or rare disease populations that national networks serve less closely.
The full report carries a profile, financials, share and development history for each company named; none of that is in this summary.
List of Key Home Infusion Therapy Market Companies Profiled
35 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Option Care Health, Inc.(United States)
- Optum Infusion Pharmacy (UnitedHealth Group Incorporated)(United States)
- Coram (CVS Health Corporation)(United States)
- BrightSpring Health Services, Inc.(United States)
- Amerita, Inc.(United States)
- KabaFusion(United States)
- Baxter International Inc.(United States)
- B. Braun Melsungen AG(Germany)
- BD (Becton, Dickinson and Company)(United States)
- ICU Medical, Inc.(United States)
- Fresenius Kabi AG(Germany)
- Soleo Health(United States)
- Triple Crown Infusion Services(United States)
- Vivo Infusion(United States)
- Premier Infusion Care(United States)
- Wellsky Corporation (CareCentrix)(United States)
- Avant Healthcare Professionals(United States)
- ARJ Infusion Services(United States)
- Eversana Life Science Services LLC(United States)
- Smiths Medical (ICU Medical)
- Moog Medical Devices Group(United States)
- Terumo Corporation(Japan)
- Nipro Corporation(Japan)
- Zyno Medical(United States)
- InfuSystem Holdings, Inc.(United States)
- Sanofi (Home infusion support)(France)
- Takeda Pharmaceutical Company Limited(Japan)
- CSL Behring (CSL Limited)(Australia)
- Fresenius Kabi Home Care(Germany)
- Medline Industries, LP(United States)
- Apria Healthcare Group(United States)
- Lincare Holdings Inc.(United States)
- Linde Healthcare Homecare
- Vitalaire (Air Liquide Santé)(France)
- Orkla Care(Norway)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 10 axes (Therapy Type, Product, Service Type, Route of Administration, Indication, Provider Type, Patient Age Group, Payer Type, Care Setting, Duration of Therapy), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 35 key companies, and the research methodology behind every estimate.
Segmentation
10 axes + regionQuestions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Home Infusion Therapy Market projected to reach?
USD 82.96 USD Billion by 2034, CAGR 8%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which segment leads the market?
Anti-Infective Therapy is the largest line by therapy type, at 26.99% of revenue in 2025.
05Who are the key companies profiled?
Option Care Health, Inc., Optum Infusion Pharmacy (UnitedHealth Group Incorporated), Coram (CVS Health Corporation), BrightSpring Health Services, Inc., Amerita, Inc., KabaFusion, Baxter International Inc., B. Braun Melsungen AG, BD (Becton, Dickinson and Company), ICU Medical, Inc., Fresenius Kabi AG, Soleo Health, Triple Crown Infusion Services, Vivo Infusion, Premier Infusion Care, Wellsky Corporation (CareCentrix), Avant Healthcare Professionals, ARJ Infusion Services, Eversana Life Science Services LLC, Smiths Medical (ICU Medical), Moog Medical Devices Group, Terumo Corporation, Nipro Corporation, Zyno Medical, InfuSystem Holdings, Inc., Sanofi (Home infusion support), Takeda Pharmaceutical Company Limited, CSL Behring (CSL Limited), Fresenius Kabi Home Care, Medline Industries, LP, Apria Healthcare Group, Lincare Holdings Inc., Linde Healthcare Homecare, Vitalaire (Air Liquide Santé), Orkla Care. Full profiles are part of the paid report.
06Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.